Question 20
At fictional Brightline Biotech, the following issue emerges in an enterprise architecture capability setup: A product group conflates a conceptual capability map with a detailed deployment inventory during a strategic review. Which safeguard should become part of future architecture reviews?
Explanation
Correct Answer
State the scope and abstraction of each architectural view before review. This safeguard addresses the recurring risk because views at different abstraction levels can describe the same enterprise without needing identical detail. Immediate remediation would be: Select an appropriate abstraction and create linked detailed models only where a decision needs them.
Incorrect Answers
This safeguard is for the dependency described by: Risk management identifies and addresses uncertainty that may affect architecture and transformation objectives. The continuing risk here is determined by: State the scope and abstraction of each architectural view before review. The targeted safeguard is “State the scope and abstraction of each architectural view before review”.
That review protects the control associated with: The four common TOGAF architecture domains are business, data, application, and technology architecture. It does not directly prevent the stated recurrence, which concerns: State the scope and abstraction of each architectural view before review. The appropriate guardrail is “State the scope and abstraction of each architectural view before review”.
This safeguard is for the dependency described by: Repository governance complements architecture work by making agreed artifacts findable and controlled. The continuing risk here is determined by: State the scope and abstraction of each architectural view before review. The targeted safeguard is “State the scope and abstraction of each architectural view before review”.